UBS Group’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $1.63M | Sell |
|
|||||
|
2025
Q2 | $2.77M | Buy |
|
|||||
|
2025
Q1 | $1.39M | Sell |
|
|||||
|
2024
Q4 | $1.96M | Buy |
|
|||||
|
2024
Q3 | $707K | Buy |
|
|||||
|
2024
Q2 | $470K | Sell |
|
|||||
|
2024
Q1 | $472K | Buy |
|
|||||
|
2023
Q4 | – | Sell |
|
|||||
|
2023
Q3 | $1.43K | Buy |
|
|||||
|
2023
Q2 | $1.65K | Sell |
|
|||||
|
2023
Q1 | $7.32K | Sell |
|
|||||
|
2022
Q4 | $11.6K | Buy |
|
|||||
|
2022
Q1 | – | Sell |
|
|||||
|
2021
Q4 | $10K | Buy |
|
|||||
|
2021
Q3 | – | Sell |
|
|||||
|
2021
Q2 | $17K | Buy |
|
|||||
|
2021
Q1 | $14K | Buy |
|
|||||
|
2020
Q4 | $25K | Buy |
|
|||||
|
2020
Q3 | – | Sell |
|
|||||
|
2020
Q2 | $43K | Buy |
|